Galapagos and Opsona Therapeutics Initiate Drug Discovery Collaboration
News Apr 22, 2009
Galapagos NV has announced that it has initiated an integrated drug discovery collaboration with Opsona Therapeutics (Dublin, Ireland).
Under the terms of the agreement, Galapagos' service division BioFocus DPI will perform biology, medicinal chemistry and ADME/PK services for an Opsona drug discovery program. Opsona will make research payments to BioFocus DPI and fund the work of 4 to 5 BioFocus DPI scientists in 2009.
"We are pleased to add Opsona Therapeutics, an emerging biotech with a promising pipeline and a successful follow-on financing round, to the growing list of BioFocus DPI customers," said Onno van de Stolpe, CEO of Galapagos. "BioFocus DPI continues to attract top biotech, pharma and not-for-profit organizations as partners, resulting in one of the most well-rounded client bases in the business."
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019